公开(公告)号：US12109183B2

公开(公告)日：2024-10-08

申请号：US17453432

申请日：2021-11-03

Applicant: Lanny Leo Johnson

Inventor： Lanny Leo Johnson

IPC: A61K31/192 ,  A61K31/18 ,  A61P31/18

CPC classification number: A61K31/192 ,  A61P31/18

Abstract: In embodiments, a method of treating a disease or condition caused by an enveloped virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals and disrupting the viral envelope of the enveloped virus. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. The enveloped virus may be a coronavirus. The enveloped virus may be a virus of the family Orthomyxoviridae.

公开(公告)号：US20240325481A1

公开(公告)日：2024-10-03

申请号：US18432324

申请日：2024-02-05

Applicant: MOREHOUSE SCHOOL OF MEDICINE

Inventor： Michael POWELL ,  Erick Vidjin’ Agnih GBODOSSOU

IPC: A61K36/42 ,  A01N63/50 ,  A01P1/00 ,  A61K31/352 ,  A61K33/30 ,  A61K38/47 ,  A61P31/18 ,  C12N15/10 ,  C12N15/82 ,  C12P19/34

CPC classification number: A61K36/42 ,  A01N63/50 ,  A01P1/00 ,  A61K31/352 ,  A61K33/30 ,  A61K38/47 ,  A61P31/18 ,  C12N15/1096 ,  C12N15/8283 ,  C12P19/34 ,  C07K2319/01

Abstract: In one aspect, nutraceutical compositions, methods of preparation and methods of use comprise a nutraceutical composition comprising an antimicrobial hevamine A-related protein from Momordica balsamina alone or in combination with one or more nutraceutical ingredients. In another aspect, a method of preventing or treating a microbial infection in a plant comprises applying an effective amount of a composition containing the hevamine A-related protein to a whole plant, plant part, or media in which the plant is growing. In a further aspect, the present application provides a transgenic plant stably transformed with a polynucleotide encoding the hevamine A-related protein.

公开(公告)号：US12102677B2

公开(公告)日：2024-10-01

申请号：US16877292

申请日：2020-05-18

Applicant: Gilead Sciences, Inc.

Inventor： Brian Moldt ,  Craig S. Pace

IPC: A61K39/21 ,  A61K31/4745 ,  A61K31/519 ,  A61P31/18 ,  C07K16/10 ,  C12Q1/70

CPC classification number: A61K39/21 ,  A61K31/4745 ,  A61K31/519 ,  A61P31/18 ,  C07K16/1063 ,  C12Q1/703 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 V3 glycan region.

公开(公告)号：US20240307528A1

公开(公告)日：2024-09-19

申请号：US18606343

申请日：2024-03-15

Applicant: VANDERBILT UNIVERSITY

Inventor： Lauren M. Walker ,  Ivelin Stefanov Georgiev

IPC: A61K39/295 ,  A61K39/00 ,  A61P31/18 ,  C12N7/00

CPC classification number: A61K39/295 ,  A61P31/18 ,  C12N7/00 ,  A61K2039/55566 ,  A61K2039/575 ,  C12N2740/16034

Abstract: The present disclosure relates to HIV vaccines and methods of use thereof. Disclosed herein are methods of preventing an infection from a human immunodeficiency virus (HIV) using a commensal microbe antigen. Further disclosed herein is a method of boosting an immune response against a human immunodeficiency virus (HIV), the method comprising administering to a subject an effective amount of a first composition comprising a commensal microbe antigen and an effective amount of a second composition comprising an HIV antigen.

公开(公告)号：US20240300905A1

公开(公告)日：2024-09-12

申请号：US18583526

申请日：2024-02-21

Applicant: Prosetta Biosciences, Inc.

Inventor： Dennis Solas ,  Anuradha F. Lingappa ,  Vishwanath R. Lingappa

IPC: C07D239/94 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D239/94 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

Abstract: Disclosed are novel heterocyclic compounds such as novel quinazoline compounds and pharmaceutical compositions thereof which may be used to treat or prevent malaria, HIV infection and cancer.

公开(公告)号：US20240293576A1

公开(公告)日：2024-09-05

申请号：US18268251

申请日：2021-12-07

Applicant: KANGLIN BIOTECH (HANGZHOU) CO., LTD

Inventor： Haoquan WU ,  Baozhen SUN ,  Ying DANG

IPC: A61K48/00 ,  A61K39/00 ,  A61P31/18 ,  C07K16/10 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K48/005 ,  A61P31/18 ,  C07K16/1063 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/76 ,  C12N2740/15043 ,  C12N2740/15052 ,  C12N2750/14143 ,  C12N2750/14152

Abstract: A nucleic acid construct for AIDS gene therapy. The nucleic acid construct comprises multiple polynucleotides encoding single chain variable region fragments of an anti-AIDS neutralizing antibody, and a polynucleotide encoding an immunoglobulin Fc fragment; the single chain variable region fragments of the anti-AIDS neutralizing antibody comprise a single chain variable region fragment capable of specifically binding to HIV, and a single chain variable region fragment capable of specifically binding to a CD4 receptor. The construct can be used for gene therapy of AIDS caused by HIV infection, and the construct can be used for expressing a bispecific/polyspecific neutralizing antibody having broad-spectrum and high-efficiency neutralizing activity in vitro and in vivo and can be used for clinical research and new drug development of AIDS gene therapy drugs delivered by recombinant viral or non-viral vectors.

公开(公告)号：US20240254104A1

公开(公告)日：2024-08-01

申请号：US18383128

申请日：2023-10-24

Applicant: Gilead Sciences, Inc.

Inventor： Bing Shi

IPC: C07D401/14 ,  A61K45/06 ,  A61P31/18

CPC classification number: C07D401/14 ,  A61P31/18 ,  A61K45/06 ,  C07B2200/13

Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

公开(公告)号：US20240240186A1

公开(公告)日：2024-07-18

申请号：US18043051

申请日：2021-09-01

Applicant: Ahmed Ibrahim Mohamed Ibrahim

Inventor： Ahmed Ibrahim Mohamed Ibrahim

IPC: C12N15/113 ,  A61P31/18

CPC classification number: C12N15/1132 ,  A61P31/18 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/3231

Abstract: Modified antisense mucleic acid molecules ending with or without chain terminating bases targeting the HIV-1 viral genomic RNA 3′ LTR region, and uses thereof for inhibiting HIV-1 replication and infection, are disclosed. The antisense mucleic acid molecules more specifically target a sequence corresponding to about nucleotide 9628 to about nucleotide 9642 of HIV-1 clone pNL4-3.

公开(公告)号：US12037343B2

公开(公告)日：2024-07-16

申请号：US18112699

申请日：2023-02-22

Applicant: Honour Lab Limited

Inventor： Kura Rathnakar Reddy ,  Kesireddy Subhash Chander Reddy ,  Guda Yadav Reddy

IPC: C07D498/18 ,  A61P31/18

CPC classification number: C07D498/18 ,  A61P31/18 ,  C07B2200/13 ,  C07D498/18 ,  C07B2200/13

Abstract: A process for preparing a sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1′,2′:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate of Formula 1 and its polymorphic form thereof.

公开(公告)号：US12024558B2

公开(公告)日：2024-07-02

申请号：US16857715

申请日：2020-04-24

Applicant: 21C Bio

Inventor： Daniel Zagury

IPC: C07K16/24 ,  A61P31/18 ,  C07K16/28 ,  A61K45/06

CPC classification number: C07K16/249 ,  A61P31/18 ,  C07K16/2866 ,  A61K45/06 ,  C12N2740/16011

Abstract: A method for treating acquired immune deficiency syndrome (AIDS) in a subject in need thereof. In particular, the method includes the administration of a combination, a kit-of-parts, a composition or a pharmaceutical composition including an interferon-alpha (IFN-α) blocking agent, a type III interferon blocking agent, an antiretroviral (ART) agent and, optionally, an interferon-beta (IFN-β) blocking agent and/or a latency-reversing agent (LRA).